Fractionated CD25-ADC Dosage Regimes for Leukemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dosage regimes for Antibody Drug Conjugates (ADCs) targeting CD25, such as those used in cancer treatment, face challenges in maintaining effective drug exposure and reducing toxicity, particularly in rapidly proliferating diseases like acute leukemia, where rapid antigenic sink effects lead to rapid clearance and peak toxicity.
Innovation Solution
Implementing fractionated dosage regimes for CD25-ADCs, where the total dose is administered in multiple partial doses throughout the treatment cycle, and tapered/elongated regimes for lymphomas, adjusting doses and cycle lengths based on patient response to maintain effective drug exposure and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a single dose of CD25-ADC is administered per treatment cycle, then the treatment protocol is simple, but rapid clearance and peak toxicity occur due to antigenic sink effects in rapidly proliferating diseases
Solution Approach 1:
The total dose of CD25-ADC is divided into multiple partial doses administered at different time points within the treatment cycle. This segmentation prevents rapid clearance by maintaining more consistent drug exposure levels, avoiding the peak toxicity associated with single high-dose administration while still achieving effective treatment outcomes.
2Ease of operation
If the total dose of CD25-ADC is administered as a single dose, then administration is convenient, but toxicity increases due to peak levels
Solution Approach 1:
The single dose is segmented into multiple smaller partial doses administered at different time points. This reduces peak plasma concentrations and associated toxicity while maintaining overall treatment efficacy, balancing convenience with safety.
Solution Approach 2:
Multiple partial doses are administered periodically throughout the treatment cycle rather than as a single bolus. This periodic administration maintains more stable drug exposure levels, reducing peak toxicity while preserving treatment effectiveness.
3Reliability
If a fractionated dosage regime is used, then toxicity is reduced and drug exposure is maintained, but the treatment protocol becomes more complex
Solution Approach 1:
The total dose is divided into manageable partial doses that can be administered at different time points. This segmentation achieves consistent drug exposure and reduced toxicity while keeping the protocol practical through structured dosing schedules.
Solution Approach 2:
The fractionated dosage regime incorporates monitoring and adjustment based on patient response and pharmacokinetic data. This feedback mechanism optimizes the dosing schedule to maintain consistent exposure and minimize toxicity while managing protocol complexity through data-driven adjustments.
4Reliability
If standard dosage regimes are used for lymphomas, then treatment is effective, but dose adjustments and cycle length changes are needed to maintain efficacy and reduce toxicity
Solution Approach 1:
The dosage regime for lymphomas is made dynamic with adjustable doses and variable cycle lengths based on patient response. This flexibility allows the protocol to adapt to individual patient needs, maintaining efficacy while reducing toxicity through personalized adjustments.
Solution Approach 2:
Dosage parameters such as dose amount and cycle length are modified based on treatment response and tolerability. This parameter adjustment optimizes the balance between efficacy and toxicity, allowing standard regimes to be tailored to individual patients without compromising treatment effectiveness.
Data Source
AI summary
The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to novel dosage regimes for the administration of ADCs which bind to CD25 (CD25-ADCS).